Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009:(193):123-59.
doi: 10.1007/978-3-540-89615-9_5.

Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering

Kenneth A Jacobson  1 , Athena M Klutz, Dilip K Tosh, Andrei A Ivanov, Delia Preti, Pier Giovanni Baraldi
Affiliations
Review

Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering

Kenneth A Jacobson et al. Handb Exp Pharmacol. 2009.

Abstract

A(3) adenosine receptor (A(3)AR) ligands have been modified to optimize their interaction with the A(3)AR. Most of these modifications have been made to the N(6) and C2 positions of adenine as well as the ribose moiety, and using a combination of these substitutions leads to the most efficacious, selective, and potent ligands. A(3)AR agonists such as IB-MECA and Cl-IB-MECA are now advancing into Phase II clinical trials for treatments targeting diseases such as cancer, arthritis, and psoriasis. Also, a wide number of compounds exerting high potency and selectivity in antagonizing the human (h)A(3)AR have been discovered. These molecules are generally characterized by a notable structural diversity, taking into account that aromatic nitrogen-containing monocyclic (thiazoles and thiadiazoles), bicyclic (isoquinoline, quinozalines, (aza)adenines), tricyclic systems (pyrazoloquinolines, triazoloquinoxalines, pyrazolotriazolopyrimidines, triazolopurines, tricyclic xanthines) and nucleoside derivatives have been identified as potent and selective A(3)AR antagonists. Probably due to the "enigmatic" physiological role of A(3)AR, whose activation may produce opposite effects (for example, concerning tissue protection in inflammatory and cancer cells) and may produce effects that are species dependent, only a few molecules have reached preclinical investigation. Indeed, the most advanced A(3)AR antagonists remain in preclinical testing. Among the antagonists described above, compound OT-7999 is expected to enter clinical trials for the treatment of glaucoma, while several thiazole derivatives are in development as antiallergic, antiasthmatic and/or antiinflammatory drugs.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structures of adenosine and widely used agonist probes of the A3AR
Fig. 2
Fig. 2
Structures of a novel, multiply substituted A3AR agonists
Fig. 3
Fig. 3
Structures of ribose ring-modified selective A3AR agonist probes
Fig. 4
Fig. 4
Structures of heterocyclic derivatives that are widely used as selective human A3AR antagonists
Fig. 5
Fig. 5
Thiazole and thiadiazole derivatives as human A3AR antagonists
Fig. 6
Fig. 6
Pyrazoloquinoline derivatives as human A3AR antagonists
Fig. 7
Fig. 7
Triazoloquinoxaline derivatives as A3AR antagonists
Fig. 8
Fig. 8
A3AR antagonists based on a pyrazolo-triazolo-pyrimidine scaffold
Fig. 9
Fig. 9
A3AR antagonists based on quinoxaline and triazolobenzotriazinone scaffolds
Fig. 10
Fig. 10
A3AR antagonists based on nonnucleoside adenine scaffolds
Fig. 11
Fig. 11
A3AR antagonists based on triazolopurine scaffolds
Fig. 12
Fig. 12
A3AR antagonists based on tricyclic xanthine scaffolds
Fig. 13
Fig. 13
A3AR antagonists based on nucleoside scaffolds
Fig. 14
Fig. 14
Compounds that interact selectively with the H272E mutant hA3AR neoceptor
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol. 2005;32:469–476. - PubMed
    1. Baraldi PG, Cacciari B, de las Infantas MJ Pineda, Romagnoli R, Spalluto G, Volpini R, Costanzi S, Vittori S, Cristalli G, Melman N, Park K-S, Ji X-d, Jacobson KA. Synthesis and biological activity of a new series of N6-arylcarbamoyl-, 2-(ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido-derivatives of adenosine-5′ -N-ethyluronamide (NECA) as A1 and A3 adenosine receptor agonists. J Med Chem. 1998;41:3174–3185. - PMC - PubMed
    1. Baraldi PG, Cacciari B, Borea PA, Varani K, Pastorin G, Da Ros T, Spalluto G. Pyrazolotriazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes? Curr Pharm Design. 2002a;8:99–110. - PubMed
    1. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Monopoli A, Ongini E, Varani K, Borea PA. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J Med Chem. 2002b;45:115–126. - PubMed
    1. Baraldi PG, Tabrizi MA, Fruttarolo F, Bovero A, Avitabile B, Preti D, Romagnoli R, Merighi S, Gessi S, Varani K, Borea PA. Recent developments in the field of A3 adenosine receptor antagonists. Drug Dev Res. 2003a;58:315–329. - PubMed

Publication types

Substances